JPWO2021092355A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021092355A5
JPWO2021092355A5 JP2022525717A JP2022525717A JPWO2021092355A5 JP WO2021092355 A5 JPWO2021092355 A5 JP WO2021092355A5 JP 2022525717 A JP2022525717 A JP 2022525717A JP 2022525717 A JP2022525717 A JP 2022525717A JP WO2021092355 A5 JPWO2021092355 A5 JP WO2021092355A5
Authority
JP
Japan
Prior art keywords
amino acid
acid modification
domain polypeptide
modification
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553813A (ja
JP7677964B2 (ja
JP2022553813A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059378 external-priority patent/WO2021092355A1/en
Publication of JP2022553813A publication Critical patent/JP2022553813A/ja
Publication of JPWO2021092355A5 publication Critical patent/JPWO2021092355A5/ja
Publication of JP2022553813A5 publication Critical patent/JP2022553813A5/ja
Priority to JP2025076140A priority Critical patent/JP2025118753A/ja
Application granted granted Critical
Publication of JP7677964B2 publication Critical patent/JP7677964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525717A 2019-11-08 2020-11-06 ヘテロIgG分子の対合のための電荷対変異の操作 Active JP7677964B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076140A JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933205P 2019-11-08 2019-11-08
US62/933,205 2019-11-08
PCT/US2020/059378 WO2021092355A1 (en) 2019-11-08 2020-11-06 Engineering charge pair mutations for pairing of hetero-igg molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076140A Division JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Publications (4)

Publication Number Publication Date
JP2022553813A JP2022553813A (ja) 2022-12-26
JPWO2021092355A5 true JPWO2021092355A5 (https=) 2023-11-14
JP2022553813A5 JP2022553813A5 (https=) 2023-11-14
JP7677964B2 JP7677964B2 (ja) 2025-05-15

Family

ID=73740489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525717A Active JP7677964B2 (ja) 2019-11-08 2020-11-06 ヘテロIgG分子の対合のための電荷対変異の操作
JP2025076140A Pending JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076140A Pending JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Country Status (8)

Country Link
US (1) US20220389119A1 (https=)
EP (2) EP4628498A3 (https=)
JP (2) JP7677964B2 (https=)
AU (1) AU2020380379A1 (https=)
CA (1) CA3160482A1 (https=)
ES (1) ES3040852T3 (https=)
MX (1) MX2022005566A (https=)
WO (1) WO2021092355A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137454A1 (en) 2023-12-21 2025-06-26 Amgen Inc. Stabilizing homodimer mutations for two cell heterodimer production

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US20140038285A1 (en) 2011-03-11 2014-02-06 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20190309092A1 (en) * 2016-07-21 2019-10-10 Development Center For Biotechnology Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
TW201930344A (zh) * 2018-01-12 2019-08-01 美商安進公司 抗pd-1抗體及治療方法

Similar Documents

Publication Publication Date Title
JP2023052214A5 (https=)
JP2020184996A5 (https=)
JP2025109759A5 (https=)
JP2018046872A5 (https=)
JP2018522541A5 (https=)
JP2023029988A5 (https=)
IL273918B1 (en) Trispecific proteins and methods of use
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
AR133615A2 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
JP2021094022A5 (https=)
RU2019129511A (ru) Белки, связывающие gd2, nkg2d и cd16
JP2020507328A5 (https=)
JP2018516546A5 (https=)
RU2012147286A (ru) Гуманизированные антитела к фактору d и их применения
RU2006126979A (ru) Мутанты анти-cd40 антитела
RU2019128204A (ru) Белки, связывающиеся с psma, nkg2d и cd16
JP2025118753A5 (https=)
JP2021521781A5 (https=)
IL279901B1 (en) Antibodies comprising a polypeptide inserted in framework 3 region
JPWO2020160560A5 (https=)
JPWO2018206790A5 (https=)
JPWO2021222578A5 (https=)
JPWO2021092355A5 (https=)
JPWO2020033664A5 (https=)
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ